<DOC>
	<DOC>NCT00741234</DOC>
	<brief_summary>This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.</brief_summary>
	<brief_title>A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criteria: Arms A &amp; B: Patients with solid tumors in Arm A and hematologic malignancies in Arm B that is classified as intermediate 1 or greater according to the International Prognostic Scoring System (IPSS) risk category for whom therapy is indicated; ECOG performance status (PS) 02; Patients must have adequate nonhematologic organ system function. Arm C: Patients with MDS that is classified as intermediate 1 or greater according to the International Prognostic Scoring System (IPSS) risk category for whom therapy is indicated; Have not been treated with azacitidine and are a candidate for treatment with azacitidine; ECOG performance status (PS) 02; Patients must have adequate nonhematologic organ system function.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>SB939</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Combination with azacitidine</keyword>
	<keyword>Solid malignancies</keyword>
	<keyword>Hematologic malignancies</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Refractory to standard therapy</keyword>
</DOC>